Provided is a homogeneous pharmaceutical composition for the treatment of an inflammatory disorder comprising a mixture of an anti-inflammatory and/or antihistaminic active ingredient selected from the group comprising azelastine or a pharmaceutically-acceptable salt thereof, a steroid selected from alclometasone, beclometasone, budesonide, ciclesonide, clobetasol, clobetasone, defiazacort, dexamethasone, diflucortolone valerate, acetonide, fluocinonide, fluocortolone, fluprednidene, flurometholone, fluticasone, halcinonide, hydrocortisone, mometasone, prednisolone, rimexolone, triamcinolone and a pharmaceutically acceptable salt of any of these compounds in a pharmaceutically acceptable aqueous carrier, and a polar lipid liposome, provided that the active ingredient is not cetirizine, wherein the concentration of active ingredient in the aqueous carrier is substantially similar, whether located inside or outside the liposomal structures and varies by ±20% when comparing concentrations inside and outside of the liposomal structures.
